M.K. Yilmaz

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

Per Pfeiffer, Dorte Nielsen, Jon Kroll Bjerregaard et al. · Annals of Oncology · 2008 · 96 citations · Full text

Medicine, Oncology, Pharmacology +14

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

Jan Alsner, M.K. Yilmaz, Per Guldberg et al. · Breast Cancer Research · 2000 · 78 citations · Full text

Medicine, Genetics, Oncology +16

Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors

Anders Christian Larsen, Jens Brøndum Frøkjær, V. Wishwanath Iyer et al. · Journal of Thrombosis and Haemostasis · 2015 · 33 citations · Full text

Medicine, Oncology, Surgery +16

Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer

Katrine R. Schønnemann, M.K. Yilmaz, Jon Kroll Bjerregaard et al. · European Journal of Cancer · 2012 · 22 citations

Medicine, Oncology, Pharmacology +17

Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer

Katrine R. Schønnemann, Hanna Jensen, M.K. Yilmaz et al. · British Journal of Cancer · 2008 · 20 citations · Full text

Medicine, Oncology, Pharmacology +17